MAIA Biotechnology, Inc. Stock-Based Compensation
MAIA Biotechnology, Inc. (MAIA) reported Stock-Based Compensation of $1.37 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-10
- MAIA Biotechnology, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $723.91K, a 9.79% decline year-over-year.
- MAIA Biotechnology, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $650.02K, a 74.99% increase year-over-year.
- MAIA Biotechnology, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $810.80K, a 16.92% increase year-over-year.
- MAIA Biotechnology, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $646.90K, a 42.05% increase year-over-year.
- MAIA Biotechnology, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $2.63M, a 37.59% increase from fiscal 2024.
- MAIA Biotechnology, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $1.91M, a 38.08% decline from fiscal 2023.
- MAIA Biotechnology, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $3.09M, a 33.19% increase from fiscal 2022.
- MAIA Biotechnology, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $2.32M, a 14.82% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $723.91K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $1.37M 10-Q · filed 2026-08-10 | $2.18M derived: sum of 3 quarters · filed 2026-08-10 | $2.83M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $650.02K 10-Q · filed 2026-05-11 | $1.46M derived: sum of 2 quarters · filed 2026-05-11 | $2.11M derived: sum of 3 quarters · filed 2026-05-11 | $2.91M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $810.80K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $1.46M derived: sum of 2 quarters · filed 2026-03-23 | $2.26M derived: sum of 3 quarters · filed 2026-08-10 | $2.63M 10-K · filed 2026-03-23 |
| 2025-09-30 | $646.90K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $1.45M derived: sum of 2 quarters · filed 2026-08-10 | $1.82M 10-Q · filed 2025-11-07 | $2.51M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $802.48K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $1.17M 10-Q · filed 2026-08-10 | $1.87M derived: sum of 3 quarters · filed 2026-08-10 | $2.32M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $371.47K 10-Q · filed 2026-05-11 | $1.06M derived: sum of 2 quarters · filed 2026-05-11 | $1.52M derived: sum of 3 quarters · filed 2026-05-11 | $1.93M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $693.44K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $1.15M derived: sum of 2 quarters · filed 2026-03-23 | $1.56M derived: sum of 3 quarters · filed 2026-03-23 | $1.91M 10-K · filed 2026-03-23 |
| 2024-09-30 | $455.39K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $869.34K derived: sum of 2 quarters · filed 2025-11-07 | $1.22M 10-Q · filed 2025-11-07 | $2.58M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | $413.95K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $763.91K 10-Q · filed 2025-08-11 | $2.13M derived: sum of 3 quarters · filed 2025-08-11 | $2.70M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $349.96K 10-Q · filed 2025-05-09 | $1.71M derived: sum of 2 quarters · filed 2025-05-09 | $2.28M derived: sum of 3 quarters · filed 2025-05-09 | $2.90M derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $1.36M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-21 | $1.93M derived: sum of 2 quarters · filed 2025-03-21 | $2.55M derived: sum of 3 quarters · filed 2025-03-21 | $3.09M 10-K · filed 2025-03-21 |
| 2023-09-30 | $570.92K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $1.19M derived: sum of 2 quarters · filed 2024-11-12 | $1.73M 10-Q · filed 2024-11-12 | $2.22M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $618.93K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $1.16M 10-Q · filed 2024-08-09 | $1.65M derived: sum of 3 quarters · filed 2024-08-09 | $2.18M derived: sum of 4 quarters · filed 2024-08-09 |
| 2023-03-31 | $537.52K 10-Q · filed 2024-05-14 | $1.03M derived: sum of 2 quarters · filed 2024-05-14 | $1.56M derived: sum of 3 quarters · filed 2024-05-14 | $2.14M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | $488.89K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $1.02M derived: sum of 2 quarters · filed 2024-03-21 | $1.61M derived: sum of 3 quarters · filed 2024-03-21 | $2.32M 10-K · filed 2024-03-21 |
| 2022-09-30 | $532.44K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $1.12M derived: sum of 2 quarters · filed 2023-11-07 | $1.83M 10-Q · filed 2023-11-07 | $2.44M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $584.77K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $1.30M 10-Q · filed 2023-08-08 | $1.91M derived: sum of 3 quarters · filed 2023-08-08 | $2.69M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $713.33K 10-Q · filed 2023-05-08 | $1.33M derived: sum of 2 quarters · filed 2023-05-08 | $2.11M derived: sum of 3 quarters · filed 2023-05-08 | |
| 2021-12-31 | $614.02K derived: 10-K 12 month − 10-Q/A 9 month · filed 2023-03-24 | $1.39M derived: sum of 2 quarters · filed 2023-03-24 | $2.72M 10-K · filed 2023-03-24 | |
| 2021-09-30 | $778.54K derived: 10-Q/A 9 month − 10-Q 6 month · filed 2023-02-06 | $2.11M 10-Q/A · filed 2023-02-06 | ||
| 2021-06-30 | $1.33M 10-Q · filed 2022-08-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |